Markt geöffnet· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Serina Therapeutics, Inc. Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress" Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson’s disease with no major clinical advances in 50+ yearsMeet with Serina’s CEO Steven LedgerRegister at AdvancingParkinsonsDisease.TribePublic.com HUNTSVILLE, AL, Sept. 23, 202
HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend o
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures – - Serina expects to report topline data from the single-
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.